Identifying molecular cancer drivers is critical for precision oncology. Multiple advanced
algorithms to identify drivers now exist, but systematic attempts to combine and optimize them on …

Introduction Large variability among Alzheimer's disease (AD) cases might impact genetic
discoveries and complicate dissection of underlying biological pathways. Methods Genome …

Cancers exhibit extensive mutational heterogeneity, and the resulting long-tail phenomenon
complicates the discovery of genes and pathways that are significantly mutated in cancer. …

The discovery of drivers of cancer has traditionally focused on protein-coding genes 1 , 2 , 3
– 4 . Here we present analyses of driver point mutations and structural variants in non-…

The IntOGen-mutations platform ( http://www.intogen.org/mutations/ ) summarizes somatic
mutations, genes and pathways involved in tumorigenesis. It identifies and visualizes cancer …

Background: The risks and benefits of coxibs, non-steroidal anti-inflammatory drugs (NSAIDs),
and aspirin treatment are under intense debate. Objective: To determine the risk of peptic …

Genetic discoveries of Alzheimer’s disease are the drivers of our understanding, and together
with polygenetic risk stratification can contribute towards planning of feasible and efficient …

While tumor genome sequencing has become widely available in clinical and research
settings, the interpretation of tumor somatic variants remains an important bottleneck. Here we …

With the ability to fully sequence tumor genomes/exomes, the quest for cancer driver genes
can now be undertaken in an unbiased manner. However, obtaining a complete catalog of …

Several large ongoing initiatives that profit from next-generation sequencing technologies
have driven—and in coming years will continue to drive—the emergence of long catalogs of …